BTK and diffuse large B-cell lymphoma: To address if CARMA1 Δlinker possesses oncogenic properties, we transduced the CD79B mutant ABC DLBCL cell line HBL1 that is sensitive to BTK inhibitor ibrutinib.23 Only oncogenic CARMA1 L225LI, but not CARMA1 Δlinker protected the ABC DLBCL cell line HBL1 from ibrutinib-induced toxicity, revealing that the Δlinker mutation can induce NF-κB, but cannot fully act like an oncogenic CARMA1 mutant (Supplementary Figures S4a–c).